Correlation of Alpha-Fetoprotein Levels with ThreePhase Contrast CT-Scan Finding in Hepatocellular Carcinoma Patients at Dr. Mohammad Hoesin General Hospital Palembangin 2022 – 2023
), Imam Suprianto(2), Legiran .(3),
(1) Medical Doctor Education Program, Faculty of Medicine, Sriwijaya University, Palembang
(2) Department of Internal Medicine, Dr. Mohammad Hoesin General Hospital, Palembang
(3) Department of Anatomy, Faculty of Medicine, Sriwijaya University, Palembang
Corresponding Author
Abstract
Background: Hepatocellular carcinoma (HCC) is the primary liver tumor, accounting for 90% of liver tumor cases. Currently, laboratory tests are needed to monitor tumor progression, predict prognosis, and determine appropriate therapy without radiological examinations, one of which is Alpha-Fetoprotein (AFP). This study aims to determine the correlation between AFP levels and three-phase contrast CT-Scan findings in HCC patients at Dr. Mohammad Hoesin General Hospital Palembang.
Methods: This was a cross-sectional design observational analytic study, using secondary data from medical records that included patient demographics, AFP, ALT, AST, direct bilirubin, indirect bilirubin, and three-phase contrast CT-Scan findings covering nodule size, nodule number, and metastasis in HCC patients treated at Dr. Mohammad Hoesin General Hospital Palembang from January 2022 – December 2023, meeting inclusion and exclusion criteria. Data were analyzed using SPSS version 22.
Results: A total of 71 samples met the inclusion and exclusion criteria. Univariate analysis showed the majority were male (83.1%), aged 50–59 years (35.2%), with elevated ALT (59.2%), AST (94.4%), direct bilirubin (91.8%), indirect bilirubin (54.1%), AFP ≥200 ng/mL (77.5%), nodule size ≥30 mm (87.3%), multiple nodules (67.6%), and no extrahepatic metastasis (74.6%). Bivariate analysis showed a significant correlation between AFP levels and nodule size on three-phase contrast CT-Scan (p-value = 0.031).
Conclusion: There is a significant correlation between AFP levels and three-phase contrast CT-Scan findings in HCC patients at Dr. Mohammad Hoesin General Hospital Palembang in 2022–2023.
Keywords
References
Asafo-Agyei KO, Samant H. Hepatocellular carcinoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2025 Apr 28]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK559177/
Martani IP, Sitanggang F, Margiani N, Widiana IG, Asih M, Ayusta IM. Correlation of abdominal CT-scan score and alpha-fetoprotein levels in hepatocellular carcinoma. Int J Integr Health Sci. 2022 Sep 30;10(2):88–93.
Kementerian Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/1355/2022 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Karsinoma Sel Hati pada Dewasa. Jakarta: Kemenkes RI; 2022.
Khoerunnissa K, Fitri SUR, Harun H. Manajemen nyeri pada Ny. I dengan HCC (hepatocellular carcinoma) di ruang rawat inap penyakit dalam RSUD Kabupaten Sumedang: studi kasus. SENTRI J Ris Ilmiah. 2023 Jul 10;2(7):2612–9.
Hanif H, Ali MJ, Susheela AT, Khan IW, Luna-Cuadros MA, Khan MM, et al. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol. 2022 Jan 14;28(2):216–29.
Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019 Dec;39(12):2214–29.
Rusie D, Mercan Stanciu A, Toma L, Iliescu EL. Correlation between serum alpha-fetoprotein and tumour size in patients with hepatocellular carcinoma treated with direct-acting antivirals. Cureus [Internet]. 2022 Apr 26 [cited 2025 Apr 28]. Available from: https://www.cureus.com/articles/94258
Nursriyanti D, Kartini A, Mutmainnah M. Analysis of alpha-fetoprotein as a staging determiner of hepatocellular carcinoma progresivity. Indones J Clin Pathol Med Lab. 2023 Jul 27;29(3):268–71.
Maharani GA, Nugraha ES, Sugianli AK. Clinical manifestations and laboratory examination findings of hepatocellular carcinoma at a tertiary care facility in Bandung: an annual observation study. Althea Med J. 2021 Sep 30;8(3):132–7.
Subbiah V, West H. Jaundice (hyperbilirubinemia) in cancer. JAMA Oncol. 2016 Aug 1;2(8):1103.
Qin S, Wang J, Yuan H, He J, Luan S, Deng Y. Liver function indicators and risk of hepatocellular carcinoma: a bidirectional mendelian randomization study. Front Genet [Internet]. 2024 Jan 22 [cited 2025 Nov 4];14. Available from: https://www.frontiersin.org/articles/10.3389/fgene.2023.1260352/full
Carr BI, Guerra V, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, et al. Association of abnormal plasma bilirubin with aggressive HCC phenotype. Semin Oncol. 2014 Mar 6;41(2):252.
Putri DRI, Maimunah U, Retnowati E. Serum AFP (alpha fetoprotein) levels profile of hepatocellular carcinoma patients in Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. Mbiom. 2022 Jan 5;32(1):6.
Carr BI, Akkiz H, Üsküdar O, Yalçın K, Guerra V, Kuran S, et al. HCC with low- and normal-serum alpha-fetoprotein levels. Clin Pract (Lond). 2018;15(1):453.
Toader E, Bancu A, Mitric DE, Constantinescu G. Interrelations between elevated alpha-fetoprotein levels and tumor morphology of patients with hepatocellular carcinoma. [Details of publication missing].
Cancer Research UK. BCLC staging system and the Child-Pugh system [Internet]. [cited 2025 Apr 28]. Available from: https://www.cancerresearchuk.org/about-cancer/liver-cancer/stages/bclc-staging-system-child-pugh-system
Hu X, Chen R, Wei Q, Xu X. The landscape of alpha fetoprotein in hepatocellular carcinoma: where are we? Int J Biol Sci. 2022 Jan 1;18(2):536–51.
Muscari F, Maulat C. Preoperative alpha-fetoprotein (AFP) in hepatocellular carcinoma (HCC): is this 50-year biomarker still up-to-date? Transl Gastroenterol Hepatol [Internet]. 2020 Oct 5 [cited 2025 Apr 28];5:73. Available from: https://tgh.amegroups.org/article/view/5737
Wang YK, Shen L, Jiao X, Zhang XT. Predictive and prognostic value of serum AFP level and its dynamic changes in advanced gastric cancer patients with elevated serum AFP. World J Gastroenterol. 2018 Jan 14;24(2):266–73.
Qian X, Liu S, Long H, Zhang S, Yan X, Yao M, et al. Reappraisal of the diagnostic value of alpha‐fetoprotein for surveillance of HBV‐related hepatocellular carcinoma in the era of antiviral therapy. J Viral Hepat. 2021 Jan;28(1):20–9.
An C, Choi YA, Choi D, Paik YH, Ahn SH, Kim MJ, et al. Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease. Clin Mol Hepatol. 2015 Sep 30;21(3):279.
Campbell C, Wang T, McNaughton AL, Barnes E, Matthews PC. Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta‐analysis. J Viral Hepat. 2020 Dec 28;28(3):493.
Article Metrics
Abstract View
: 357 times
Download : 165 times
DOI: 10.24871/2622025114-119
Refbacks
- There are currently no refbacks.
